Drug Profile
Research programme: Gram negative infection therapeutics - ContraFect/Rockefeller University
Alternative Names: Gram-negative lysins - Contrafect/Rockfeller University; Lysin GN123Latest Information Update: 25 Apr 2024
Price :
$50
*
At a glance
- Originator ContraFect; Rockefeller University
- Class Antibacterials; Endolysins; Recombinant proteins
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Gram-negative infections
Most Recent Events
- 04 Dec 2023 Discontinued for Gram-negative infections in USA (unspecified route) as ContraFect filed for voluntary bankruptcy under chapter 11 of the US Bankruptcy code
- 28 May 2023 No recent reports of development identified for research development in Gram-negative-infections in USA
- 03 May 2021 ContraFect has patent protection for lysins in treating Gram-negative infections in USA